Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).

Devalingam MahalingamSiqi ChenPing XieHoura LoghmaniThomas HeinemanAparna KalyanSheetal KircherIrene B HelenowskiXinlei MiVictoria MaurerMatt CoffeyMary MulcahyAl- BensonBin Zhang

Published in: British journal of cancer (2023)

Pelareorep and pembrolizumab showed modest efficacy in unselected patients, although potential immune and metabolic biomarkers were identified to warrant further evaluation.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
advanced non small cell lung cancer
prognostic factors
peritoneal dialysis
climate change
epidermal growth factor receptor